Introduction
The endothelial glycocalyx (eGC), a carbohydrate-rich gel-like mesh of large anionic polymers, lines the luminal side of the endothelium along the entire vascular tree. 1, 2 As the primary physical barrier between blood and the vessel wall, the glycocalyx serves as a firewall against endothelial hyperpermeability, a life-threatening feature of acute systemic inflammatory diseases in which vascular leakage initiates a vicious cycle of tissue oedema and hypoxia that can lead to multiple organ failure and even death. [3] [4] [5] The most prominent components of the eGC are highly sulphated glycosaminoglycans (mainly heparan and chondroitin sulphate) attached to core proteoglycans, especially those from the syndecan family. 6, 7 In large conduit vessels, eGC removal limits bioavailability of nitric oxide, resulting in blunted shear stress-dependent vasodilation. In capillaries and postcapillary venules, the negatively charged gel-like matrix of the eGC provides resistance to water permeability (hydraulic conductivity) and contributes to the proportion of albumin molecules 'reflected' back into plasma by the vessel wall (reflection coefficient). 8 Along with various incorporated proteins of plasmatic and endothelial origin, the eGC attains thickness of up to 2 mm and thus can be slightly thicker than the endothelial cells themselves. 1, 9, 10 Enzymatic thinning of the glycocalyx exposes previously hidden endothelial surface adhesion molecules, including ICAM-1 and VCAM-1, allowing neutrophils to recognize and adhere to the endothelial surface. 11, 12 Additionally, enzymatic digestion of the eGC by the heparan sulphate (HS)-cleaving enzyme, Heparanase, results in enhanced permeability. 13 Glycocalyx damage in vivo has been observed in response to inflammatory agents, such as endotoxin, 14 TNF-alpha, 15 oxidized LDL 16 and excess atrial natriuretic peptides, 17 as well as during hyperglycaemia. 18 However, because visualization and quantification of the fragile glycocalyx structure in vitro is methodologically challenging, signalling pathways and downstream events controlling its disruption and refurbishment are poorly understood. 9, 19 The vascular-associated receptor tyrosine kinase Tie2 and its agonistic ligand Angiopoietin-1 (Angpt-1) were discovered in the mid-1990s by Sato et al. 20 and Davis et al. 21 While early studies in Angpt-1-/-and Tie2-/-knockout mice, which die in utero owing to severe vascular defects, revealed the importance of operational Angpt-1-Tie2 signalling for developmental angiogenesis, 20, 21 tonic Tie2 activation by Angpt1 was subsequently identified as an important control pathway to promote microvascular barrier function and anti-inflammatory properties. 22 Its intrinsic antagonist, Angiopoietin-2 (Angpt-2), is a secreted protein released from endothelial Weibel-Palade bodies upon inflammatory stimulation. 23 The release of Angpt-2 disrupts the constitutive Angpt-1/ Tie2 signalling by preventing Angpt-1 from binding to the receptor. 22, 24, 25 Mechanistically, withdrawal of Tie2 phosphorylation is believed to facilitate activation of other signalling systems, which then promote permeability by increasing the number and size of gaps that form at endothelial cell junctions through cellular contraction and junctional disintegration (paracellular hyperpermeability). 26 Emerging evidence points toward a 'double barrier concept' in which both the endothelial cell layer and eGC play a role in maintaining the vascular barrier. 27 Given that Angpt-2 promotes vascular leakage in endothelial architecture, we hypothesize that Angpt-2 impairs eGC structure and function. To corroborate this, we analysed eGC structure and function in vitro via atomic force microscopy and in vivo by performing a series of permeability experiments.
Methods

Antibodies and reagents
Antibodies and reagents used are provided in detail in the, see Supplementary material online, Materials and Methods.
Cell culture
The human umbilical vein endothelial cell line EA.hy 926 (kindly provided by Cora-Jean Edgell, University of North Carolina, Chapel Hill, NC, USA) was grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Karlsruhe, Germany) supplemented with 1% Pen/Strep and 10% heatinactivated foetal calf serum (hFCS; PAA Laboratories, Pasching, Austria), as previously described. 28 As Ea.hY926 is a hybridoma cell line derived by fusing human umbilical vein endothelial cells with the permanent human lung epithelial cell line A549, we cannot rule out that the their eGC may have some epithelial characteristics. However, human umbilical venous endothelial cells (HUVECs) showed exactly the same eGC decrease in immunofluorescence and AFM experiments (see Supplementary material online, Figure S2A and B). Primary HUVECs were isolated and grown in culture as previously described. 29 Further details are stated in the, see Supplementary material online, Materials and Methods section.
Atomic force microscopy
The thickness and stiffness of the eGC were determined using the atomic force microscope (AFM) nano-indentation technique as described previously in detail. 19, 30, 31 Briefly, a triangular cantilever with a mounted spherical tip periodically indents the cells. A laser beam is used to quantify the cantilever deflection. Also knowing the force acting on the cantilever, the piezo displacement, and the deflection sensitivity, the thickness of the eGC can be calculated. A more detailed description of the AFM method is provided in the, see Supplementary material online, Materials and Methods.
Confocal fluorescence immunocytochemistry
CS and HS were stained as previously described in detail. 32 A more detailed description of the confocal fluorescence immunocytochemistry is provided in, see Supplementary material online, Materials and Methods.
Heparanase activity assay
Heparanase activity was determined via enzyme-linked immunosorbent assay according to the manufacturer's instructions in lysates of EA.hy926 cells incubated with different substances (Takara, Otsu, Japan).
2.6
In vivo animal studies 2.6.1 Animals C57BL/6J (WT) mice, 6-10 weeks old, were purchased from Harlan Laboratories (Venray, The Netherlands) and kept under specific pathogen-free conditions. Mice were sacrificed under isoflurane anaesthesia immediately after the experiments. All experimental animal procedures were approved by the local authorities (District Government and District Veterinary Office, Münster, Germany). The animal experiments were performed conform the guidelines from Directive 2010/63/ EU of the European Parliament on the protection of animals used for scientific purposes.
Permeability assay of the skin (Miles assay)
Increased vascular permeability of the skin was achieved via the so-called Miles assay, as previously described in detail. 33 In brief, mice under isoflurane anaesthesia (Forene 100%, Abbott, Ludwigshafen, Germany) received intradermal injections (i.d.) of histamine (10 or 100 mM in 20 mL PBS). Thirty minutes before histamine injection, mice received Angpt-2 (65 ng/g mouse), Evans Blue (150 mL, 0.5% in PBS), and 150 mg of the Heparanase inhibitor NAH or an equivalent volume of PBS (as control for NAH) intravenously. Evans Blue facilitates visualization and quantification of vascular leakage. Mice were sacrificed 30 min after histamine application and skins were harvested. Punch biopsies of 8 mm diameter were taken, weighed, and stored in formamide for 24 h at room temperature. Evans Blue intensity in supernatants was measured photometrically at 630 nm in a microplate reader (BioTek, Bad Friedrichshall, Germany).
Perfused boundary region measurement
To visualize the back skin microvasculature in vivo, sidestream dark field (SDF) intravital microscopy (MicroVision Medical Inc., Wallingford, PA) was performed to detect the dynamic lateral red blood cell (RBC) movement into the eGC of the microcirculation (expressed as perfused boundary region (PBR)). Further details are stated in the, see Supplementary material online, Materials and Methods section.
Reverse passive Arthus reaction
Reverse passive Arthus reaction as a model of acute cutaneous inflammation was induced as described previously in detail. 34 Further details are stated in the, see Supplementary material online, Materials and Methods section. groups were analysed using the one-way analysis of variance with Bonferroni's correction for multiple comparison. All tests were two sided and significance was accepted at P < 0.05. To test for differences in the glycocalyx thickness and cortical stiffness between groups, a nested analysis of variance was performed to account for both the number of observations from a single experiment and the number of experiments. Tukey correction was used to control the family wise error rate in the situation of multiple comparisons. GraphPad Prism Version 6 (GraphPad Prism Software Inc, San Diego, CA, USA) and SPSS 20 (IBM, Armonk, NY, USA) were used for data analysis and figure preparation.
Statistical analysis
Results
Angpt-2 is a negative regulator of the eGC in vitro
To begin, we used AFM to identify effects of Angpt-2 on the nanomechanics of the eGC of living endothelial cells (EA.hy926 cell line) in vitro. Similar to previous investigations, 19, 30 at least two different slopes could be identified depending on the indentation depth of the cantilever. The first slope (indentation depth of the first 100 nm) was previously shown to represent the thickness/stiffness of the eGC, whereas the second steep slope reflects the thickness/stiffness of the plasma membrane including the underlying cortical actin web (cell cortex) 19, 30 (see Supplementary material online, Figure S3 ). Given that glycocalyx research has traditionally focused on thickness as a surrogate for structural integrity, we focus on eGC thickness; glycocalyx stiffness results were basically identical to those for thickness in all experiments (data not shown). Incubation with Angpt-2 (100 ng/mL) for 60 min led to a 53% reduction in eGC thickness compared to control (183 ± 5 vs. 86 ± 2 nm, P < 0.0001). The observed effect was comparable to the eGC-lowering capacity of heparinase I (1 Sigma Unit/mL) ( Figure 1A ). Neither longer exposure times nor higher doses of heparinase I could reduce thickness further (data not shown).
Multiple lines of evidence suggest that Angpt-1 and Angpt-2 is an agonist-antagonist pair of ligands at the Tie-2 receptor. 25 Consistent with this notion, Angpt-2-induced reduction of glycocalyx thickness was completely blocked by addition of the Tie2 agonistic ligand Angpt-1, suggesting that the effects of Angpt-2 on eGC thickness are Tie2 dependent ( Figure 1B) . Next, we measured cortical stiffness to exclude the possibility that the eGC slope of the force distance curve partially contains simultaneous deformation of the plasma membrane and the underlying cortical actin web (cell cortex). As shown by static and time-resolved AFM experiments, Angpt-2 had virtually no effect on cortical stiffness ( Figure 1C and D) . To further validate our results, we visualized and quantified two major Figure 1E and F) .
Similar results were obtained in primary cultured HUVECs (see Supplementary material online, Figure 2A and B). Taken together, this data indicate that Angpt-2 is a negative regulator of the eGC.
Angpt-2-induced degradation of eGC is heparanase dependent
Angpt-2 þ/-and Angpt-2 -/-mice are well protected from vascular leakage and mortality during experimental sepsis and thioglycollate-induced peritonitis. 35, 36 Recently, Schmidt et al. 5 provided compelling evidence that glycocalyx degradation in murine endotoxemia involves the specific loss of HS due to activation of endothelial heparanase, an HS-specific glukuronidase. We therefore tested whether Angpt-2 induces eGC degradation in a heparanase-dependent manner. In fact, competitive inhibition of heparanase by either heparin (see Supplementary material on line, Figure S4 ) or the non-anticoagulant heparin fragment NAH completely prevented the rapid (<10 min) decline in glycocalyx thickness in response to Angpt-2 ( Figure 2A and B) . These results were essentially reproducible in fresh preparations of aortic endothelium (see Supplementary material online, Figure S4 ). Treatment of EA.hy926 cells with Angpt-2 for 60 min increased HS degradation activity in supernatants ( Figure 2C ) and simultaneously diminished intracellular heparanase abundance ( Figure 2D) . Notably, the amount of heparanase released by Angpt-2 was not different from the response induced by high-dose LPS ( Figure 2E ). Immunofluorescence studies further revealed that heparanase colocalized with Rab7 in perinuclear vesicles, suggesting that heparanase is stored within and rapidly released from late endosomal/ lysosomal compartments. In line with this hypothesis, pre-treatment with the selective lysosome lysing compound GPN prevented Angpt-2-induced glycocalyx thinning ( Figure 2F ). Wang et al. 38 recently reported that cortical actin disassembly and stress actin formation were prerequisite for heparanase secretion from human endothelial cells. Given that Tie2 signalling plays a pivotal role in actin remodelling, we next sought to understand the specific intracellular pathways involved. Parikh et al. 26 have previously shown that Angpt-2 induces actomyosin contractile activity in response to phosphorylation of myosin light chain via Rho-kinase, a downstream target of RhoA, and myosin light-chain kinase (MLCK). Co-treatment of Angpt-2-stimulated EA.hy926 cells with specific inhibitors of Rho-kinase (Y27632, 10 lM) or MLCK (ML-7, 10 lM) completely eliminated the Angpt-2 effect, whereas inhibitor treatment alone had no obvious effect on glycocalyx thickness ( Figure 3A and B) . Similarly, inhibition of Ca 2þ /calmodulin-dependent protein kinase II (KN-93, 10 lM), a Ca 2þ -dependent/operated upstream effector of MLCK, was sufficient to prevent Angpt-2-induced glycocalyx loss ( Figure 3C ). Finally, we investigated whether release of endogenous (i.e., pre-stored) Angpt-2 is essential for eGC damage. Indeed, co-treatment of LPS-stimulated EA.hy926 cells with either Angpt-1 (400 ng/mL) or a highly specific Angpt-2 inhibitor (L1-10, 200 ng/mL) completely eliminated eGC damage induced by LPS ( Figure 3D ). In summary, these findings indicate that Angpt-2-induced withdrawal of Tie2-signalling causes heparanase secretion from distinctive cellular stores with consecutive enzymatic degradation of the eGC in a nonredundant manner.
Angpt-2-induced eGC thinning increases vascular permeability in vivo
Our aim was to investigate the influence of eGC-degradation or eGCprotection on vascular permeability. As this is challenging in vitro, we focused on in vivo assays, e.g., the Miles assay, to study the eGC function. Firstly, we had to reproduce eGC-thinning effects of Angpt-2 in vivo. Therefore, we performed as a proof of principle experiment sidestream dark field microscopy in the back skin of mice. Using intravital sidestream darkfield imaging together with an automated acquisition and analysis approach, we calculated the PBR, it is possible to detect loss of the eGC expressed by a higher dynamic lateral RBC movement into the eGC of capillaries, which is called PBR (Figure 4A and C) . We could show that It is hard to identify the net contribution of glycocalyx to permeability changes in response to Angpt-2, because Angpt-2 is supposed to drive gap formation. 26 We therefore used histamine to ensure maximal gap formation, regardless of the presence of Angpt-2. Importantly, histamine acts as a powerful mediator of endothelial gap formation but does not seem to affect/digest the eGC. 27 Having confirmed the latter finding in our experimental setup (see Supplementary material online, Figure S5 ), we were then able to identify the net effect of oedema formation induced by heparanase in response to systemically administered Angpt-2. Figure 5A displays the principle and hypothesis of this experiment. Administration of the heparanase inhibitor NAH along with Angpt-2 significantly reduced vascular permeability compared to solvent (PBS) co-administered with Angpt-2 following intradermal injection of 10 mM histamine (biopsy weight: -30.7%, P < 0.05; Evans Blue dye content: -35.1%, P < 0.05). Histamine was chosen because it allowed selective widening of inter-endothelial gaps 39 without affecting the eGC. 27 Figure 5B shows an example of the harvested back skins used to quantify vascular permeability. Barrier-protective effects of heparanase inhibition were still detectable with a 10-fold higher dose (100 mM) of histamine (biopsy weight: -16.6%, P < 0.05; Evans Blue dye content: -26.4%, P < 0.05) ( Figure 5C and D) . Emerging evidence suggests that the glycocalyx serves as a barrier to leukocyte adhesion and that its shedding may be an essential part of the inflammatory response. Conceptually, the thickness of the eGC (>0.5 lm in vivo) exceeds the length of apical-based selectins, and as such it has been proposed that the in vivo eGC forms a 'cloak' that conceals endothelial adhesion sites from passing neutrophils. 40 Using the reverse passive Arthus reaction as a model of immune complex-mediated cutaneous vasculitis, we tested whether Angpt-2-mediated eGC digestion also aggravates neutrophil recruitment and infiltration to the endothelium. Figure 6A schematically shows the principle and hypothesis behind this experiment, whereas Figure 6B shows two representative mice back skins used to quantify MPO activity and oedema formation. Administration of the heparanase inhibitor NAH along with Angpt-2 significantly reduced MPO activity (-26.1%, P < 0.001) and oedema formation (-28.4%, P < 0.0001) compared to placebo (PBS) co-administered with Angpt-2 ( Figure 6C and D) . Taken together, two different functional assays suggest that the eGC is a significant first barrier against plasma leakage and leukocyte extravasation and that Angpt-2 contributes to its digestion via heparanase in vivo.
Discussion
To our knowledge, this is the first report on the direct effect of Angpt-2 on structure and function of the eGC. Using live-cell AFM and intravital microscopy, we show that Angpt-2 mediates breakdown of the eGC. Mechanistically, Angpt-2 causes heparanase secretion from distinctive cellular storage pools with consecutive enzymatic degradation of the eGC in vitro. Corresponding in vivo experiments indicate that heparanasedependent eGC breakdown induced by exogenous Angpt-2 contributes to plasma leakage and leukocyte extravasation. Within the broader context of vascular permeability, our results extend our understanding of the Angpt/Tie2 system as being a shared and non-redundant regulator of the two both layers of the entire vascular double barrier: the endothelial cell and the eGC. From a teleological perspective, the shared regulation of the two layers of the vascular barrier through a single non-redundant signalling Angpt-2-induced heparanase secretion causes a rapid enzymatic degradation of glycocalyx HS, consistent with its dominant role in glycocalyx structure. 6, 7 Intriguingly, the release of heparanase upon Angpt-2 stimulation seems to involve the same signalling pathways (MLCK, Rho-kinase, and Ca 2þ /calmodulin-dependent protein kinase II) required for Angpt-2-induced actin stress fibre and paracellular gap formation. 26 Consistent with this notion, Wang et al. 38 reported that endothelial heparanase secretion in response to glucose depends on Ca 2þ influx and the formation of stress actin, both of which are also controlled by the Angpt-Tie2 system. 26, [41] [42] [43] It is conceivable that transient deprivation of cortical actin and/or stress actin formation as a track for vesicle translocation from the endosomal/lysosomal compartment towards the plasma membrane is necessary for heparanase secretion. 38, 44, 45 From our experiments, we cannot determine whether gap formation and eGC loss are two separate but parallel events controlled by a common upstream mechanism, or if heparanase release is an inevitable, secondary event during actin remodelling. Though the entire pathway remains to be mapped in following studies, there are immediate therapeutic implications to the data presented here. Previous studies on the Angpt-Tie2 system did not focus on nor account for the eGC being an additional component of the vascular barrier. It is possible that the protection against plasma leakage conferred by either exogenous Tie2 stimulation, Angpt-2 scavenging, or genetic deletion of Angpt-2 in different models of sepsis is partly due to the preservation of the eGC. 35, 46 To our knowledge, there are three studies linking glycocalyx properties with the Angpt/Tie2 system. In 2009, Salmon et al. 47 observed in an elegant microperfusion study that reduced basal water permeability and albumin reflection upon Angpt-1 treatment was accompanied by an increase in glycocalyx thickness. In addition, Angpt-1 prevented pronase-induced hyperpermeability, presumably through restoration of the eGC. Although Angpt-1 prevented the eGC damage induced by Angpt-2, neither Angpt-1 nor Angpt-2 inhibition increased eGC thickness over basal levels in the current study. These seemingly discordant results may be explained by differences in the methodologies used to measure glycocalyx thickness (electron microscopy vs. AFM).
From a nano-mechanical perspective, it is possible that our AFM Another explanation could be that the absence of fluid shear stress and/ or reduced abundance of plasma proteins may result in partial collapse of the glycocalyx during the AFM procedure. However, consistent with Salmon's findings, Angpt-2 inhibition conferred protection against LPSinduced glycocalyx damage in our study. Only recently Han et al. 48 reported that an Angpt-2 scavenging/Tie2 activating antibody ameliorates the loss of HS content and preserves glycocalyx depth in pulmonary microvessels of septic mice. Intriguingly, this protective effect was associated with a reduced up-regulation of heparanse expression in septic lungs, indicating a putative role of Tie2 in the transcriptional regulation of heparanase. Finally, Gurnik et al. 49 found a disrupted eGC in brain microvessels from Angpt-2-overexpressing mice compared with WT mice using electron microscopy. In summary, these findings support the concept that the Angpt-Tie2 system plays a non-redundant role in glycocalyx regulation (as already documented for endothelial gap formation 35, 36, 42 ). Cytoskeletal rearrangement and eGC damage are known to increase endothelial permeability. 5, 26, 38 Although disintegration of both layers simultaneously affects permeability, the specific contribution of each layer to permeability regulation is not well established. According to the 'double-barrier concept' introduced by Rehm et al. 27 in 2004, perturbation of one component without altering the other should result in no increase or only a moderate increase in vascular permeability. Any additional alteration of the second competent barrier, however, leads to a major increase in vascular permeability. Only recently, an intra-vital microscopy study by Schmidt et al. 50 provided compelling evidence that prevention of heparanase-mediated degradation of the pulmonary eGC was sufficient to eliminate vascular hyperpermeability and leukocyte adhesion in murine endotoxemia. Furthermore, Wang et al. 51 has shown that LPS-induced eGC damage and increased permeability can be attenuated by ulinastatin-mediated Heparanase inhibition. Quantification of the net contribution of Angpt-2-induced eGC damage, however, provided quite complex. First, Angpt-2 was assumed to affect both layers of the double barrier at the same time; second, consistent with its facilitatorrole, Angpt-2 alone exerts only a weak effect on vascular permeability 26, 41, 52 ; and, third, lack of fluid shear stress and/or reduced abundance of plasma proteins may result in an immature eGC, thus precluding permeability analysis in vitro. We employed a modified Miles assay to overcome these issues. Angpt-2-induced loss of the eGC seems to specifically increase permeability by no less than 25% in our experiments. However, this effect may be overestimated since cleavage of HS glycosaminoglycan polysaccharides from the basement membrane may partly contribute to increased permeability. 53 Another limitation of our in vivo model is that we did not test the time dependency and additive effects of injected substances separately. However, as the Angpt-2 induced downregulation of Tie2 should last 3 h 54 and histamine was given intradermally 30 min after systemic Angpt-2 injection, there should be a considerable synergistic effect on gap formation. To visualize small vessels in vivo after Angpt-2 treatment, we used sidestream darkfield microscopy as a new method to calculate the PBR and could show an increase in PBR after Angpt-2 injection. However, this technique has some limitations. Most importantly, the perfused diameter and the PBR are not measured directly but are only calculated based on the movement and radial displacement of RBCs. Although the methodology has been carefully validated, 55 we cannot rule out that unspecific Angpt-2-induced disturbances of the microcirculation may have mimicked an (false-positive) increase in PBR. In summary, our data reveal a crucial role for Angpt-2 in the regulation of the eGC. The results advance our understanding of the Angpt/Tie2 ligand-receptor system as a shared and concurrent gatekeeper of both layers of the vascular double barrier: the endothelial cell and the eGC. Given that Tie2 axis drugs will be available in the future, therapeutic protection of the eGC might become a feasible and important treatment goal in diseases characterized by with vascular leakage.
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